This post was originally published on this site
ARTHUR KUAN
CEO / CHAIRMAN
CG ONCOLOGY
WHY: The 34-year-old leads research for bladder cancer treatments that investors have called “game changers.” Went public in January 2024 after raising $380M in an initial public offering, marking the largest IPO for an OC-based firm in the last three years. Shares of the Irvine-based company soared 96% on its first day as a publicly traded company. Market cap now tops $1.8B. Company has secured more than $300M since its founding in 2010, making it one of the region’s better-funded life science companies.
IN THE NEWS: Company in April posted positive results from its Phase 3 BOND003 clinical trial. It reported a 75.5% remission rate in patients with high-risk non-muscle invasive bladder cancer, causing shares to jump 25% in one day. Said next step is to submit a Biologics License Applications (BLA) to the FDA in the second half of this year. NOTABLE: Completed his master’s in biotechnology at John Hopkins University. Founding member of healthcare-focused venture firm Ally Bridge Group in Hong Kong. Ally Bridge was an early investor in CG, Cold Genesys at the time, having contributed to its Series A round in 2014. Left Ally Bridge to join CG as vice president of research and clinical project management before taking over as CEO in 2016. IN HIS WORDS: “We’re looking forward to growing the company. We are trying to save people’s lives.”
